+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Paternal cyclophosphamide treatment of rats causes fetal loss and malformations without affecting male fertility



Paternal cyclophosphamide treatment of rats causes fetal loss and malformations without affecting male fertility



Nature 316(6024): 144-146



The use of cytotoxic, mutagenic and carcinogenic agents as treatment for various types of cancer may be particularly hazardous in men of reproductive age as there exists the possibility that this may lead to congenital malformations in the progeny. Such agents can affect fertility and other aspects of male reproductive function, for example, treatment with anti-cancer drugs such as cyclophosphamide has been associated with oligozoospermia, azoospermia and increased levels of serum follicle-stimulating hormone (FSH). Depending on the cumulative dose and the duration of treatment, spermatogenesis often returns but this may take years. The relevance of the effects of such chemicals on the male reproductive system to the offspring is poorly understood. We have set out to determine whether present tests of male reproductive function (that is, endocrine status, numbers of spermatozoa, fertility) can predict deleterious effects of a paternally administered agent on the offspring. Here, we report that chronic administration in rats of low doses of the widely used drug cyclophosphamide had minimal effects on the male reproductive system and fertility, but resulted in malformations and retardation of growth in the surviving fetuses and a high frequency of fetal death. Thus, adverse effects on the fetus cannot be predicted from the effects of a drug on the male reproductive system.

Accession: 040918056

Download citation: RISBibTeXText

PMID: 4040213

DOI: 10.1038/316144a0


Related references

Increased postimplantation loss and malformations among the F2 progeny of male rats chronically treated with cyclophosphamide. Teratology 45(6): 671-678, 1992

A time-course study of chronic paternal cyclophosphamide treatment in rats: effects on pregnancy outcome and the male reproductive and hematologic systems. Biology of Reproduction 37(2): 317-326, 1987

Chronic low dose cyclophosphamide treatment of adult male rats effect of fertility pregnancy outcome and progeny. Biology of Reproduction 34(2): 275-283, 1986

Fertility treatments, congenital malformations, fetal loss, and childhood acute leukemia: the ESCALE study (SFCE). Pediatric Blood & Cancer 60(2): 301-308, 2013

Tumors and malformations in the adult offspring of cyclophosphamide treated and control male rats preliminary communication. Mutation Research 229(2): 239-246, 1990

Effects of cyclophosphamide administration on different fertility evaluation tests in male rats. Teratology 53(5): 30A, 1996

The Influence of Methotrexate Treatment on Male Fertility and Pregnancy Outcome After Paternal Exposure. Inflammatory Bowel Diseases 23(4): 561-569, 2017

Paternal cyclophosphamide treatment causes postimplantation loss via inner cell mass-specific cell death. Teratology 45(3): 313-318, 1992

Effect of methomyl on fetal development and male fertility in rats. Bulletin of Animal Health and Production in Africa 38(3): 229-232, 1990

Paternal or fetal antigen immunotherapy for recurrent fetal loss. Tecnologica: 8-10, 1995

Paternal treatment with cisplatin impairs reproduction of adult male offspring in rats. Reproductive Toxicology 32(4): 425-433, 2012

Restoration of sexual function and fertility by fetal hypothalamic transplant in impotent aged male rats. Neurobiology of Aging 8(5): 465-472, 1987

Inheritance of paternal centrioles and male fertility. International Journal of Gynecology & Obstetrics (ABSTR SUPPL): 209, 1991

Exposure of neonatal male rats to estrogen induces abnormal morphology of the penis and loss of fertility. Reproductive Toxicology 18(2): 265-274, 2004

Study to establish the evaluation method for male fertility 4 Optimal administration period for detection of male fertility disorders in rats. Journal of Toxicological Sciences 20(4): 496, 1995